638220-39-0

Basic information

• Product Name: 6-METHYL-CHROMAN-4-YLAMINE
• Synonyms: 6-METHYL-CHROMAN-4-YLAMINE;6-methylchroman-4-amine;2H-1-Benzopyran-4-amine, 3,4-dihydro-6-methyl-;6-methyl-3,4-dihydro-2H-chromen-4-ylamine hydrochloride;3,4-Dihydro-6-methyl-2H-1-benzopyran-4-amine;6-Methyl-3,4-dihydro-2H-chroMen-4-aMine
• CAS NO: 638220-39-0
• Molecular Formula: C10H13NO
• Molecular Weight: 163.22
• Mol File: 638220-39-0.mol

Chemical Properties

• Boiling Point: 256℃
• Flash Point: 110℃
• Appearance: /
• Density: 1.079
• Vapor Pressure: 0.016mmHg at 25°C
• Refractive Index: 1.553
• Storage Temp.: 2-8°C
• PKA: 8.84±0.20(Predicted)
• CAS DataBase Reference: 6-METHYL-CHROMAN-4-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHYL-CHROMAN-4-YLAMINE(638220-39-0)
• EPA Substance Registry System: 6-METHYL-CHROMAN-4-YLAMINE(638220-39-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 638220-39-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-METHYL-CHROMAN-4-YLAMINE is used as a pharmaceutical candidate for its neuroprotective and anti-inflammatory properties, making it suitable for the development of new drugs targeting oxidative stress-related conditions and diseases.
Used in Food Industry:
6-METHYL-CHROMAN-4-YLAMINE is used as an antioxidant and radical scavenger to inhibit oxidation processes and prevent the formation of free radicals, thereby enhancing the shelf life and quality of food products.
Used in Antioxidant Applications:
6-METHYL-CHROMAN-4-YLAMINE is used as an antioxidant agent for its ability to inhibit oxidation processes, which can help protect cells and tissues from oxidative damage and reduce the risk of various diseases associated with oxidative stress.
Used in Neuroprotective Applications:
6-METHYL-CHROMAN-4-YLAMINE is used as a neuroprotective agent for its potential to protect neurons from oxidative damage and inflammation, making it a promising candidate for the treatment of neurodegenerative diseases.
Used in Anti-Inflammatory Applications:
6-METHYL-CHROMAN-4-YLAMINE is used as an anti-inflammatory agent for its ability to reduce inflammation and oxidative stress, which can be beneficial in the treatment of various inflammatory conditions and diseases.

InChI:InChI=1/C10H13NO/c1-7-2-3-10-8(6-7)9(11)4-5-12-10/h2-3,6,9H,4-5,11H2,1H3

Upstream product

• 39513-75-2 6-methyl-4-chromanone 
• 890839-03-9 6-methyl-chroman-4-one O-methyl-oxime 

Relevant articles and documents

Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists

Novel chroman and tetrahydroquinoline ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that aryl substituents on the 7- or 8-position of both bicyclic scaffolds imparted the best in vitro potency at TRPV1. The most potent chroman ureas were assessed in chronic and acute pain models, and compounds with the ability to cross the blood-brain barrier were shown to be highly efficacious. The tetrahydroquinoline ureas were found to be potent CYP3A4 inhibitors, but replacement of bulky substituents at the nitrogen atom of the tetrahydroisoquinoline moiety with small groups such as methyl can minimize the inhibition.

ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF

The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar1, L1, R1, R2, R3, R4, R5, Y1, Y2, and Y3, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula I:

7-Substituted Purine Derivatives for Immunosuppression

The present invention provides novel purinone and related derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula III:

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.